Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Key Inclusion Criteria: * Histologically confirmed diagnosis of B-cell lymphoma * No previous systemic treatment for lymphoma * Subject demonstrates need for treatment for lymphoma * Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease * Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy * Adequate performance status * Required baseline laboratory data within protocol-specified parameters Key Exclusion Criteria: * Known history of transformed lymphoma or diffuse large cell lymphoid malignancy * Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment * Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis * Ongoing inflammatory bowel disease * Known human immunodeficiency virus (HIV) infection * History of prior allogeneic bone marrow progenitor cell or solid organ transplantation * Ongoing immunosuppressive therapy, including systemic corticosteroids (\> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytop…